Top News
Prostate Cancer Recurrence Risk Higher With Extensive Positive Margins
SABR May Up Survival in Oligometastatic Cancers
Follicular Lymphoma With Extranodal Disease Only: When to Suspect Systemic Disease
Private Insurers Pay 241 Percent of What Medicare Would Pay
Colorectal Cancer Incidence Increasing in Younger Adults
Quitting Smoking Lowers Risk for Bladder Cancer Postmenopause
PARP Inhibitor Did Not Increase SCLC Response to Immune Checkpoint Blockade
Percutaneous Ablation Appropriate for Localized Renal Tumors
Combination Therapy May Improve Outcomes in Patients With Chronic Lymphocytic Leukemia
EDITORIAL ADVISORY BOARD
E. David Crawford, MD
Jeffrey M. Farma, MD
Featured
-
The Untold Story of the Longest Persisting CAR-T Cells in CLL
A deep dive into how CAR-T cells evolved in 2 patients with chronic lymphocytic leukemia who have had the longest complete remissions to date. -
Barriers to Cancer Clinical Trial Enrollment
This fact sheet discusses potential barriers to participation in cancer clinical trials. -
The Confounding Case of Venetoclax in Multiple Myeloma
It is still unclear why patients in the experimental arm in BELLINI saw a worse overall survival (OS) rate than those receiving placebo. -
In-House or Centralized Testing? Debating Whether Genomic Sequencing Is Best Conducted at Home
Genomic analysis of tumors and tests measuring certain biomarkers can be done in-house or sent out. What are the costs and benefits of each approach? -
ctDNA Makes Progress as an Early Treatment Indicator in Breast Cancer
Despite its limitations, ctDNA is emerging as a potentially powerful diagnostic tool. -
Yoga and Cancer
This fact sheet reviews the use of yoga as a supportive care tool for patients with cancer.
More Features
What Do Surrogate End Points Actually Predict?
As understanding of cancer improves, drug development could become accelerated, necessitating a means for determining whether a drug is actually effective.
Enhanced Reimbursement Incentives for Generic Cancer Drugs Found Not to Affect Prescribing Patterns
Critics of the study say they are not surprised by the study’s conclusions, as oncologists make treatment decisions based on best treatment course, not money.
Muscle Complaints Are a Frequent Side Effect of TKI Use in CML, but What Causes Them?
Many CML patients on TKI treatment report muscle complaints, but there has been little work to find out why. A new study sought to find out more about the nature of these complaints and to undercover a biological mechanism to explain them.
Predictors of TKI Response in CML Remain Elusive
High-throughput analytics failed to identify reliable markers to predict TKI response in CML.
Susceptibility to Radiation-Induced Breast Cancer Following Treatment for Hodgkin Lymphoma
Genetic variants associated with radiation-induced breast cancer include MYC-adjacent oncogene PVT1.
